The Bcl-2 (B-cell lymphoma 2) protein Bax (Bcl-2 associated X, apoptosis regulator) can commit cells to apoptosis via outer mitochondrial membrane permeabilization. Bax activity is controlled in healthy cells by prosurvival Bcl-2 proteins. C-terminal Bax transmembrane domain interactions were implicated recently in Bax pore formation. Here, we show that the isolated transmembrane domains of Bax, Bcl-x L (B-cell lymphoma-extra large), and Bcl-2 can mediate interactions between Bax and prosurvival proteins inside the membrane in the absence of apoptotic stimuli. Bcl-2 protein transmembrane domains specifically homooligomerize and heterooligomerize in bacterial and mitochondrial membranes. Their interactions participate in the regulation of Bcl-2 proteins, thus modulating apoptotic activity. Our results suggest that interactions between the transmembrane domains of Bax and antiapoptotic Bcl-2 proteins represent a previously unappreciated level of apoptosis regulation.
The Bcl-2 (B-cell lymphoma 2) protein Bax (Bcl-2 associated X, apoptosis regulator) can commit cells to apoptosis via outer mitochondrial membrane permeabilization. Bax activity is controlled in healthy cells by prosurvival Bcl-2 proteins. C-terminal Bax transmembrane domain interactions were implicated recently in Bax pore formation. Here, we show that the isolated transmembrane domains of Bax, Bcl-x L (B-cell lymphoma-extra large), and Bcl-2 can mediate interactions between Bax and prosurvival proteins inside the membrane in the absence of apoptotic stimuli. Bcl-2 protein transmembrane domains specifically homooligomerize and heterooligomerize in bacterial and mitochondrial membranes. Their interactions participate in the regulation of Bcl-2 proteins, thus modulating apoptotic activity. Our results suggest that interactions between the transmembrane domains of Bax and antiapoptotic Bcl-2 proteins represent a previously unappreciated level of apoptosis regulation.
apoptosis | Bcl-2 | mitochondria | oligomerization | transmembrane T he mitochondrial apoptosis program can activate the proapoptotic Bcl-2 (B-cell lymphoma 2) protein Bax (Bcl-2 associated X, apoptosis regulator) in response to stress, resulting in outer mitochondrial membrane (OMM) permeabilization and the release of cytochrome c (cyt c) and other proteins of the intermembrane space into the cytosol. The Bcl-2 family controls Bax activity and thus the integrity of the OMM (1-3). Prosurvival Bcl-2 proteins harbor four Bcl-2 homology domains [BH1-4, as represented by Bcl-2, Bcl-x L (B-cell lymphoma-extra large), or Mcl-1] and counteract proapoptotic Bcl-2 proteins with three BH domains (BH1-3; e.g., Bax or Bak). The diverse group of BH3-only proteins regulates both prosurvival and proapoptotic Bcl-2 proteins. Prosurvival Bcl-2 proteins either inhibit Bax via direct interaction or by sequestering "activator" BH3-only proteins, thus preventing their interaction with Bax (4-9).
In healthy cells, newly synthesized Bax initially translocates to the OMM, but efficiently retrotranslocates to the cytoplasm, depending on prosurvival Bcl-2 proteins (10, 11) . Bax shuttling thus establishes an equilibrium between cytosolic and mitochondrially anchored molecules (10, 12) , determining the cellular response to apoptotic stress (13) . Upon the induction of apoptosis, Bax and Bak interact and at least partially insert into the OMM (14) (15) (16) . Regulatory interactions between Bax and other Bcl-2 proteins can only be observed in the presence of the OMM or liposomes (17, 18) . Recent studies suggest that Bax is inserted in mitochondrial membranes as a monomer that oligomerizes once inserted (19) (20) (21) . These studies also have shown that Bcl-x L inhibits Bax by dissociating Bax oligomers. However, the contribution of the different protein domains to oligomer formation and apoptosis modulation within the membrane is still unclear.
Transmembrane domains (TMDs) can mediate protein-protein interactions within membranes and be involved in signal transduction across bilayers via changes in the oligomeric state or protein conformation (22) (23) (24) . The Bax TMD targets fusion proteins to the OMM; its deletion results in cytosolic Bax localization and impaired Bax activity (25) . Analysis of the active Bax membrane topology suggests that the TMD could play a central role in Bax oligomerization (26) . Förster resonance energy transfer studies have shown that Bax forms homooligomers in the mitochondria through TMD interactions (27) . Bcl-x L -mediated Bax retrotranslocation into the cytosol depends on the Bcl-x L TMD, suggesting the involvement of TMD interactions in Bax inhibition (13) . In addition, distance mapping of cysteine-labeled Bax variants in large unilamellar vesicles suggests a role of the Bax TMD in the formation of potential Bax pore structures (28) . Thus, TMD interactions could be involved in Bax regulation, oligomerization, and pore formation.
Here, we report the self-association and interaction of the TMDs of Bax, Bcl-2, and Bcl-x L in the biological membranes of living cells in the absence and presence of apoptosis induction. The TMDs mediate homooligomerization and heterooligomerization between proapoptotic Bax, and prosurvival Bcl-2 and Bcl-x L members independent of extramembrane protein regions, modulating the response to apoptosis signaling.
Significance
Bcl-2 (B-cell lymphoma 2) proteins are key regulators of apoptosis. The recruitment of the predominantly cytosolic Bcl-2 protein Bax (Bcl-2 associated X, apoptosis regulator) to the mitochondria is associated with mitochondrial outer membrane permeabilization and apoptosis. We report specific interactions between the transmembrane domains (TMDs) of Bax and the prosurvival Bcl-x L (B-cell lymphoma-extra large) and Bcl-2 proteins. Our results demonstrate that these interactions occur in nonapoptotic human cells and participate in the regulation of Bcl-2 proteins, introducing the concept of modulation mitochondrial apoptosis signaling by TMD-mediated Bcl-2 protein interactions.
Results and Discussion
Bax, Bcl-x L , and Bcl-2 TMDs Homooligomerize in E. coli Membranes.
Interactions between Bcl-2 proteins require membranes (29, 30) . Therefore, the potential homooligomerization of Bax, Bcl-2, and Bcl-x L TMDs was analyzed in living cells by using the ToxRed system (31) . In this assay, TMDs were inserted between the transcriptional activation domain (ToxR) and maltose-binding protein (MBP), targeted to the periplasm (32) . Transcriptional activation of the cholera toxin promoter strictly depends on ToxR oligomerization (33) . Consequently, TMD oligomerization resulted in red fluorescent protein (RFP) expression (Fig. 1A) . The level of fluorescence is proportional to the analyzed oligomerization. Fusion protein functionality, orientation, and membrane insertion were controlled by the growth of mutant Escherichia coli on maltose as the sole carbon source dependent on MBP activity in the periplasm (Fig. S1 ). The TMDs of Bcl-x L and Bcl-2 induced as much RFP fluorescence and therefore oligomerization as the positive control, glycophorin A (GpA) TMD (Fig. 1B) . Similar levels of Bax TMD generated the highest fluorescence levels (Fig. 1B) . The emission spectra of ToxRed chimeras corroborate the formation of Bcl-2 protein homooligomers (Fig. S2) . Interestingly, the amino acid sequences of the Bax, Bcl-x L , and Bcl-2 TMDs (Table 1) revealed central glycine residues as potential sites for strong helix-helix interactions through ridge-into-grove arrangements, as observed for other interacting TMDs (24, (34) (35) (36) (37) . These glycine residues are evolutionarily conserved (Fig. S3 ). Structural studies have demonstrated that conserved glycine residues rarely face lipids, and many of them participate in close helix-helix packing (38) . Accordingly, Fig. 1C shows disruptive effects for mutations Bcl-2 G227I, Bcl-x L G222I, and, to a lesser extent, for Bax G179I (similar to the GpA G83I mutant) (39) . The helix-breaking G179P mutation [similar to GpA (40) ] resulted in an even-more-prominent disruption of Bax TMD homooligomerization, whereas mutation of the conserved Bax F176 had no effect. In all cases, expression levels, as determined by Western blotting, were comparable ( Fig. 1 B and C) . Furthermore, appropriate membrane insertion of chimeric proteins was confirmed (Fig. S4) . Therefore, the TMDs of Bax, Bcl-2, and Bcl-x L mediate specific and efficient homooligomerization in a biological membrane.
Bax, Bcl-x L , and Bcl-2 TMDs Form Oligomers in Mitochondrial Membranes.
Next, we analyzed the self-association capacity of Bax, Bcl-x L , and Bcl-2 TMDs in nonapoptotic human cells using bimolecular fluorescence complementation (BiFC) assays (41) . TMDs were fused with two nonfluorescent fragments (VN: 1-155 amino acids, I152L; and VC: 155-238 amino acids, A206K) of the venus fluorescent protein to assess whether TMD interactions would reconstitute fluorescence of venus ( Fig. 2A) (42) . VN and VC constructs fused to the same TMD were cotransfected in HCT116 colon carcinoma cells. This process, indeed, resulted in Bax, Bcl-2, and Bcl-x L TMD homooligomerization in the absence of apoptotic stimuli (Fig. 2B) . The nonoligomerizing TMD of the abundant mitochondrial Tom20 protein was used as a negative control for overcrowding. Bcl-x L oligomerization is still controversial; some cross-linking experiments suggest oligomer formation, whereas other studies using detergents or structural data in nanodiscs have revealed monomers (43) . However, extraction of transmembrane proteins with detergents could dissociate them, and nanodisc studies are highly dependent on the lipid composition (44) . A striking advantage of the BiFC assays is the observation of interactions in eukaryotic membranes. The Western blot analysis confirmed comparable expression levels of the VN and VC constructs. Therefore, the observed fluorescence values indicate different association levels and agree with the results obtained in the ToxRed system (Fig. 1B and Fig. S5 ), where self-association of the proapoptotic Bax TMD caused the highest fluorescence signal. The analysis of the intracellular distribution of TMD fusion proteins by confocal microscopy revealed mitochondrial localization (Fig. 2C) .
Next, single amino-acid substitutions were introduced into the TMDs to analyze the sequence specificity of TMD homooligomerization (Fig. 2D) . The subcellular distribution of chimeric constructs was also corroborated by cellular fractionation (Fig. 2E ). In agreement with ToxRed homooligomerization experiments, strong interference by Bax G179P (see also Fig. 2C , bottom row), Bcl-2 G227I, and Bcl-x L G222I was observed, whereas Bax F176A again exhibited no difference from the wild-type construct. The Bcl-2 L225P and Bcl-x L G217P mutants also exhibited strong interference with TMD oligomerization. Therefore, Bax, Bcl-2, and Bcl-x L TMDs form specific homooligomers within the OMM.
Bax TMD Interacts with Prosurvival Bcl-2 Protein TMDs. Because of the specific homooligomerization of the Bax, Bcl-2, and Bcl-x L TMDs in nonapoptotic cells, the possibility of heterooligomerization and regulatory interactions between these TMDs was tested. (Table 1) were transformed into MM39 cells. The fluorescence signal (ʎ exc 570, ʎ em 620 nm) obtained with the ToxRed system for Bax, Bcl-x L , and Bcl-2 TMDs is shown. Red bars highlight interactions. The GpA TMD and nondimerizing TMD GpA G83I variant served as positive and negative controls, respectively. Western blotting of MBP revealed equivalent expression levels. (C) Homooligomerization assay of wild-type and variants of the Bax, Bcl-x L , and Bcl-2 TMDs. Fusion protein functionality, orientation, and membrane insertion of all variants were controlled by growth on minimum medium (Fig. S4) . Reduction in fluorescence indicates the disruption of homooligomerization (white bars). Results obtained with mutations that apparently do not interfere with homooligomerization are depicted in brown. Error bars represent the mean ± SD; n ≥ 3. Western blotting of MBP revealed equivalent expression levels for all chimeras. P values according to Dunnett's test are displayed. *P < 0.05; **P < 0.01; ***P < 0.001. Central glycine residues are shown in bold, and mutated Phe 176 from Bax is in italics.
To this end, we analyzed the competition between homomerization of ToxR fusion proteins and their heterooligomerization with fusion proteins with the disabled ToxR DNA binding domain (ToxR*; Fig. 3A ). Disabled ToxR* fusion proteins can interact with ToxR proteins in a dominant-negative fashion; the resulting decrease in RFP expression thus indicates the ratio between homooligomerization and heterooligomerization. In this assay, competition between homooligomer and heterooligomer formation with similar affinities results in a 50% decrease in fluorescence (31) .
The Bax TMD has a strong tendency to self-associate (Figs. 1B and 3B). As expected, this signal was attenuated by coexpressing ToxR*/BaxTMD, whereas the ToxR*/GpATMD did not interfere with RFP expression (Fig. 3B) . Interestingly, both TMDs derived from prosurvival Bcl-2 or Bcl-x L proteins interfered with Bax TMD homooligomerization to at least the extent of the Bax TMD. These results suggest a strong capability of the TMDs of prosurvival Bcl-2 proteins to heterooligomerize with the Bax TMD. Accordingly, the Bax TMD reduced Bcl-x L and Bcl-2 homooligomerization ( Fig. 3 C and D) . Strikingly, the Bcl-2 and Bcl-x L TMDs did not interfere with each other's homooligomerization, suggesting an absence of heterooligomerization between both prosurvival Bcl-2 TMDs (Fig. 3 C and D) . These results suggest that the interactions of prosurvival Bcl-2 protein TMDs enable heterooligomerization with Bax. Interactions between the Bax TMD and TMDs of prosurvival Bcl-2 proteins could participate in Bax regulation, because the membrane-bound form of Bcl-x L has been described to insert only its TMD into the membrane (43) . Therefore, the influence of TMD interactions on Bax regulation was tested by analyzing isolated mitochondria permeabilization in HCT116 Bak knockout (KO) cells in the presence or absence of corresponding Bax, Bcl-x L , Bcl-2, and Fis1 TMD segments. The presence of high Bcl-x L or Bcl-2 TMD concentrations inhibited the release of Smac from mitochondria ( Error bars represent the mean ± SD, n ≥ 3. P values according to Dunnett's test are displayed. *P < 0.05; **P < 0.01; ***P < 0.001.
TMDs interferes with Bax-induced OMM permeabilization. However, other mechanisms, such as competition for a common binding site or interference in the interaction with other OMM components, could also account for the observed effects. Bcl-x L TMD-dependent inhibition of OMM permeabilization is not complete, because cyt c is still released (Fig. S6) . Lack of inhibition by the Bax TMD is particularly interesting, because the peptide concentration exceeded the native Bax protein concentrations. Therefore, symmetric Bax, and perhaps Bak oligomers, as recently suggested (27, 45) , could tolerate the association of multiple TMDs. Alternatively, other oligomeric Bax structures could be more prominent in OMM permeabilization.
Bax TMD Interacts with Full-Length Proteins. Next, we tested the potential of Bax, Bcl-2, and Bcl-x L TMDs to interact with fulllength proteins. Self-associating VN/VC-BaxTMD or VN/VC-Bcl-2TMD chimeras that reconstitute the venus fluorescent protein were coexpressed with antiapoptotic and proapoptotic full-length proteins in HCT116 cells (Fig. 4A) . BaxTMD homooligomerization was disturbed in the presence of full-length Bax, Bcl-2, and Bcl-x L ( Fig. 4B and Fig. S7A ). Therefore, full-length proteins bind to the Bax TMD-derived chimeras, corroborating the interactions between the isolated TMD segments (Fig. 3 B-D) . Interestingly, Bax and Bcl-2 proteins interfered with Bcl-2 TMD homooligomerization, but Bcl-x L protein did not ( Fig. 4C and Fig. S7B ). The mitochondrial location of overexpressed TMD constructs was corroborated by subcellular fractionation experiments (Fig. 4 B and C, Right). The specificity and TMD dependence of these interactions were tested by replacing the Bax TMD with the corresponding Bcl-x L TMD segment in the full-length Bax protein (Bax/Bcl-x Ltail ). Bax/Bcl-x Ltail interfered with Bax, but slightly altered Bcl-2 TMD homooligomerization (Fig. 4 B and C) . On the other hand, the reciprocal chimera harboring the BaxTMD in fulllength Bcl-x L (Bcl-x L /Bax tail ) bound to Bax and Bcl-2 (Fig. 4 B and  C) . Then, the interaction between the TMDs of Bax and Bcl-2 and full-length proteins is specific and depends on the TMD of the Bcl-2 protein. These results were also corroborated in Bax/Bak double-KO (DKO) cells (Figs. S8 and S9 ).
Bax TMD Modulates Interactions with Endogenous Proteins and
Activates Apoptosis. The Bcl-x L TMD is involved in Bax retrotranslocation, and we thus focused our studies on the interactions between both TMDs (13) . A fusion of the Bax TMD to the C terminus of the biotin ligase BirA (BirA/BaxTMD) biotinylated endogenous Bax and Bcl-x L in nonapoptotic HCT116 cells ( interactions. Our results are supported by Bak (and Bax) TMD interfaces mediating homooligomerization in the absence of BH3-dependent interactions (45) . Mutant Bax proteins lacking either alpha 5 (Δ5) or alpha 6 (Δ6) helices, which are potentially relevant for membrane insertion and pore formation (19, 26, 28, 46) , retained the capacity for Bax association in mitochondrial membranes (Fig.  5C ), emphasizing the role of the TMDs in early protein interactions. Both BirA/BaxFL and BirA/BaxTMD bound to wild-type Bcl-x L (Fig.  5D ). This binding was strongly reduced when cells were cotransfected with the nonfunctional Bcl-x L G138A mutant (47) . Strikingly, some capacity for heterooligomer formation was retained (Fig. 5D ) and matches the Bax TMD capability of oligomer formation, corroborating the contribution of Bax TMD interactions with prosurvival Bcl-x L . Mutations in the BirA/BaxTMD construct that decrease Bax homooligomerization, such as G179P, provoked a similar decrease in Bcl-x L biotinylation (Fig. 5E ), suggesting at least a partial common interface for heterooligomerization and homooligomerization.
Together, our results demonstrate that interactions between the TMDs of Bax and Bcl-x L occur in the OMM of human cells before the induction of apoptosis. The analysis of a potential role of TMD interactions in apoptosis induction revealed that the ectopic expression of the BaxTMD in HCT116 cells induces caspase-3/7 activation (Fig. 6 ). BaxTMD G179P, but not BaxTMD F176A, interferes with this activation, in good agreement with the impact of these mutants on oligomerization in Fig. 2D . Furthermore, cotransfection with antiapoptotic Bcl-2-and Bcl-x L TMD-derived constructs or with full-length proteins significantly reduced apoptosis activation (Fig. 6) . Therefore, Bcl-2 protein TMD interactions are involved in mitochondrial apoptosis signaling.
Conclusion
Antiapoptotic and proapoptotic Bcl-2 proteins regulate mitochondrial apoptosis signaling, and thus the cell fate, by dynamic interactions. Interplay between the BH3 domains and hydrophobic grooves of the respective interaction partner have been characterized (48) . In the present study, we discovered interactions between the TMDs of Bax, Bcl-2, and Bcl-x L that occur in nonapoptotic cells and modulate mitochondrial apoptosis signaling. The consistent picture that emerges from these studies is that Bcl-2 and Bcl-xL TMDs could have the ability to regulate Bax pore-forming activity by means of direct competition, leading to the formation of heterooligomers that abate Bax homooligomer formation and OMM permeabilization. The existence of Bax TMD interactions has been proposed based on cross-linking experiments (49, 50) and 3D models (28) and has been suggested to contribute to the enlargement of the Bax pore (51). Although not as tight as hydrophobic groove and BH3 domain interactions, TMD-TMD interactions are sufficient for heterooligomerization and homooligomerization of Bcl-2 proteins. Therefore, Bax dimers and oligomers could facilitate lateral sorting in the OMM or the formation of Bcl-2 protein-containing complexes (52) . TMD-TMD interactions are consistent with models of Bax activation, suggesting separation of helices α5 and α6 (27, 53) and the concerted insertion of both helices into the OMM (51, 54) . Conversely, Bax activation according to the clamp model would require a sequential mechanism to allow formation of antiparallel TMD interactions (28) . The observation of TMD-TMD interactions between Bcl-2 proteins in proliferating cells further emphasizes the necessity to assess the protein conformation of Bax and other Bcl-2 proteins. These new surfaces of proteinprotein interaction among proapoptotic and prosurvival members could represent attractive targets for selective drug design.
Methods
Methods are fully described in SI Methods. ToxRed chimeric constructs were generated by specific primer annealing of Bcl-2 protein TMDs in the HindIII/ XhoI restriction sites of ToxRed vectors (Table 1 and Table S1 ). The maltose complementation assay was performed as described (39, 55) .
ToxRed Oligomerization Assays. ToxR-Bcl-2 TMD constructs (Table S1) were transformed into the malE mutant E. coli MM39 strain. For RFP measurements, 24-well plates were adjusted to equivalent growth (OD 600 0.6-0.8), and the RFP emission spectra were collected by a Wallac 1420 Workstation (ʎ exc 560 and ʎ em 595 nm).
BiFC-TMD Assays. BiFC assays were performed as described (56) . An improved BiFC assay with a high signal-to-noise ratio was selected to avoid background interference (57, 58) . The system was adapted to clone Bax, Bcl-x L , and Bcl-2 TMDs at the C terminus of venus protein fragments, according to their natural topology in full-length proteins.
BirA Interaction Partner Identification. HCT116 Bax/Bak DKO cells were transfected with pcDNA3-mycBioID-Bax plasmid, resulting in the expression of myctagged BirA/Bax fusion. The cell lysate was incubated with streptavidin agarose beads (Thermo) at 4°C overnight. Input and bead samples were resolved on a 10% (wt/vol) SDS/PAGE and analyzed by Western blot for the indicated proteins. and Bcl-x L full-length proteins on caspase-3/7 activity induced by VN-BaxTMD in HCT116 cells is shown. Caspase 3/7 activity was analyzed in cytosolic extracts 24 h after transfection. Error bars represent the mean ± SD, n = 3. P values according to Dunnett's test are displayed. **P < 0.01; ***P < 0.001.
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SI Methods
Design and Cloning of ToxRed Bcl-2 TMD Constructs. The ToxRed plasmids were provided by William DeGrado, School of Pharmacy, University of California, San Francisco. ToxRed chimeric constructs were generated by specific primer annealing of Bcl-2 protein TMDs in the HindIII/XhoI restriction sites of ToxRed vectors (Table S1 ). All transmembrane sequences were codon-optimized for E. coli expression. TMD mutants were created by using standard sitedirected mutagenesis with a commercially available Stratagene Quikchange II kit (Agilent). All molecular biology techniques were performed according to standard procedures. The maltose complementation assay was performed as described (39, 55) .
ToxRed Oligomerization Assays. ToxR-Bcl-2 TMD constructs were transformed into the malE mutant E. coli MM39 strain and plated in maltose minimal-agar medium. Cells were grown in selective LB to OD 600 0.2 and incubated with shaking at 37°C in maltoseminimal medium until OD 600 0.8. For RFP measurements, 24-well plates were adjusted to equivalent growth (OD 600 0.6-0.8) and the RFP emission spectra collected by a Wallac 1420 Workstation (ʎ exc 560 and ʎ em 595 nm). The ToxRed dominant-negative experiments to study heterooligomer formation were performed as described (31) .
Western Blotting for ToxRed-TMD Constructs. Whole-cell extracts were subjected to SDS/PAGE, transferred to nitrocellulose membranes, and blotted following standard procedures. MBP primary antibody (no. E8038S) was purchased from New England Biolabs.
TOXRED Fluorometry Studies. Saturated cultures (5 mL) were centrifuged at 1,500 × g for 10 min and pellets resuspended in 500 μL of freshly prepared FasterBreak Cell Lysis Reagent 1× (Promega). After 15 min of mixing, lysates were centrifuged at 1,500 × g and fluorescence measured (λ exc 584 and λ em 595-610 nm) in a spectrofluorometer.
BiFC Fluorometry Studies. A total of 8 × 10 5 cotransfected cells (VN and VC vectors) were scraped on ice, collected in PBS, and centrifuged at 2,500 rpm for 5 min at 4°C. Cell pellets were resuspended in 500 μL of lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 5 mM MgCl 2 , and 0.5% Triton X-100 containing 0.1 mM PMSF, 20 μM leupeptin, and 1 μM pepstatin) and mixed for 30 min on a rotary platform at 4°C. Cell lysates were centrifuged at 10,000 rpm for 5 min at 4°C
, and fluorescence emission spectra were recorded (λ exc 515 and λ em 520-650 nm).
Cell Culture. Human colorectal carcinoma HCT116 cells, provided by Richard Youle, Porter Neuroscience Research Center, Bethesda, and Bert Vogelstein, Johns Hopkins University School of Medicine, Baltimore, were grown in McCoy's 5A medium supplemented with 10% FBS. Cultures were maintained at 37°C in a 5% CO 2 atmosphere.
BiFC-TMD Assays. BiFC assays were performed as described (56) . An improved BiFC assay with a high signal-to-noise ratio was selected to avoid background interference (57, 58) . The system was adapted to clone Bax, Bcl-x L , and Bcl-2 TMDs at the C terminus of venus protein fragments according to their natural topology in full-length proteins. In the case of Bax, some oligomerization experiments were performed in both orientations due to the high levels of cell death induction observed when the C-terminal orientation was used that interfere with proper analysis in some experimental conditions. BiFC plasmids from Addgene (catalog nos. 27097 and 22011) were modified to insert a linker (GGGGSGGGGSSGR for VN and RPACKIPNDLKQKVM-NHDKQKSGR for VC) and a NotI restriction site behind the venus fragment to clone the Bcl-2 protein TMDs in the adequate topology. Venus VN-terminal (1-154, I152L ) and VC-terminal (155-238, A206K) fragments were fused with the TMD region of the different Bcl-2 proteins (Table 1 ). The human Bcl-2 TMD sequences were introduced by oligonucleotide annealing (Table  S1 ). BiFC-Bcl-2 protein TMD mutant constructs were obtained by using standard site-directed mutagenesis with the Stratagene Quikchange II kit. VN and VC constructs have c-myc and HA tags, respectively, for appropriate detection.
HCT116 cells at 60-70% confluence in 96-well black plates were cotransfected with 0.05-0.1 μg of DNA constructs by using Lipofectamine 2000 or Turbofect, according to the manufacturer's instructions. Transfected cells were incubated at 37°C for 18 h to avoid toxicity, and then venus fluorescence emission was measured by using a Wallac 1420 Workstation (ʎ exc 510 and ʎ em 535 nm). Transfection efficiency was monitored using a GFP-Bcl-2 TMD construct and maintained >70% in all experiments. For Western blotting analysis, cells were seeded in six-well plates, transfected with 0.5-1 μg of DNA constructs by using Turbofect, and incubated for 18 h. Total protein extracts were analyzed for chimera expression by using primary antibodies against HA C29F4 (catalog no. 3724S) and c-myc 9B11 (catalog no. 2276S) (Cell Signaling).
Smac Release from Isolated Mitochondria. Mitochondria from HCT116 cells were purified as described (13) . To study Smac release in isolated mitochondria in vitro, mitochondrial outer membrane permeabilization was induced with recombinant tBid (R&D Systems; 10 nM). Mitochondria (50 μg) were incubated with TMD peptides at the indicated concentrations in 200 μL of KCl buffer [125 mM KCl, 4 mM MgCl 2 , 5 mM Na 2 HPO 4 , 5 mM succinate, 0.5 mM EGTA, 15 mM Hepes-KOH (pH 7.4), and 5 μM rotenone] for 15 min at 30°C. The mitochondria were then centrifuged for 5 min at 13,000 × g at 4°C. Mitochondrial pellets corresponding to 5 μg of protein and the corresponding volume of supernatant fractions were resolved by SDS/PAGE and transferred to a nitrocellulose membrane. Smac (antibody) was monitored in the supernatant and pellet by Western blot to monitor release. Bax (antibody) and VDAC (antibody) served as loading controls.
BirA Interaction Partner Identification. HCT116 Bax/Bak DKO cells were transfected with pcDNA3-mycBioID-Bax plasmid, resulting in the expression of myc-tagged Bax/BirA fusion. After cell harvest in ice-cold PBS, the cell pellet was resuspended in SEM buffer [10 mM Hepes, pH 7.2, 250 mM sucrose, containing complete proteinase inhibitor mix (Roche), and 0.2% Triton X-100] and lysed. The cell lysate was cleared via centrifugation at 120,000 × g at 4°C for 30 min, applied to a concentrator column (Vivaspin 3000 MWCO; GE Healthcare), and washed (100 mM Tris·HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, and complete proteinase inhibitor mix; Roche). The input sample (2.5%) was separated, and the remaining lysate was incubated with streptavidin agarose beads (Thermo) at 4°C overnight. After incubation, the beads were washed four times with washing buffer and finally boiled in SDS loading buffer. Input and bead samples were resolved on a 10% SDS/PAGE and analyzed by Western blot for the indicated proteins.
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Immunofluorescence. HCT116 cells were seeded on coverslips (50% confluence), transfected with equal amounts of VC/VN BiFC-TMD constructs, and incubated for 24 h at 37°C. Mitochondria were stained with 500 nM MitoTracker (Invitrogen) for 20 min at 37°C, and cells were fixed with 4% paraformaldehyde. The coverslips were mounted on glass slides with Mowiol/DAPI (Sigma). Confocal microscopy images were obtained by using a laser-scanning microscope 510 with a 63× objective.
Apoptosis Assays. Cell extracts were prepared from cells seeded in 3.5-cm-diameter plates at a density of 4 × 10 5 cells per plate. The cells were transfected with 0.75 μg of VN-Bax in the presence of a mock pcDNA3.1 (0.75 μg) vector or the same vector containing Bcl-2 or Bcl-x L sequences. Cells were harvested after 18 h, and the pellets were resuspended in 50 μL of extraction buffer (50 mM Pipes, 50 mM KCl, 5 mM EDTA, 2 mM MgCl 2 , and 2 mM DTT, supplemented with protease inhibitor mixture from Sigma), and kept on ice for 5 min. After the pellets were frozen and thawed three times, the cell lysates were centrifuged at 14,000 rpm for 5 min, and supernatants were collected. The total protein concentration of these cell extracts was quantified by using the bicinchoninic acid method. A total of 50 μg was mixed with 200 μL of caspase assay buffer (PBS, 10% glycerol, 0.1 mM EDTA, and 2 mM DTT) containing 20 μM Ac-DEVD-afc. Caspase activity was monitored after the release of fluorescent afc at 37°C by using a Wallac 1420 Workstation (λ exc 400 and λ em 508 nm).
Statistical Analysis. All of the values represent the mean ± SD of at least three independent experiments. Significance was determined by one-way ANOVA, applying the Dunnett's test using GraphPad software. P < 0.05 was considered significant. Wavelength (nm) Fluorescence intensity (a.u) Fig. S2 . Emission spectra for the ToxRed assay. For fluorescence measurements of RFP, samples from bacterial lysates were excited at 584 nm, and emission spectra were recorded from 595 to 650 nm. The mock line is for whole-cell lysates containing a control plasmid without a ctx::mCherry reporter. Fig. S3 . Multisequence alignment of Bcl-2 TMDs from different species. Evolutionarily conserved glycine residues are boxed in red, and mutated leucine and phenylalanine residues from Bcl-2 and Bax sequences, respectively, are boxed in blue. 
